Review on Kidney metanephric adenoma a, with data on clinics, and the genes involved.
Classification
Metanephric adenoma belongs to the category of Metanephric tumor in the WHO histological classification of tumors of the kidney.
Etiology
Although previously suggested to be derived from persistent blastema, metanephric adenoma is currently thought to develop from maturation of nephroblastoma.
Epidemiology
Metanephric adenomas are rare (<1% of renal epithelial neoplasms) but occur across a wide range of patients, from infants to older individuals.. The peak age frequency is 40 to 69 years. There is a female predominance (2.3:1). Ten percent of patients present with polycythemia.
Clinics
Mostly metanephric adenomas are incidentally discovered. Some patients present with hematuria and abdominal or flank pain.
Pathology
Grossly, metanephric adenomas demonstrate a tan to fleshy white homogeneous cut surface (Fig. 1A ) (Grignon et al., 2016) . Most tumors are welldemarcated but lack a true capsule and are typically unilateral. Microscopically, the tumor is highly cellular and chiefly composed of tightly packed primitive tubules; papillary or glomeruloid structures may also be seen. The individual tumor cells are small, bland and cuboidal with scant cytoplasm, and round-to-oval nuclei with smooth chromatin, and inconspicuous nucleoli (Fig. 1B) 
Treatment
Surgical excision.
Prognosis
The vast majority of metanephric adenomas behave in a benign fashion. Cases of regional lymph node metastasis and sarcomatoid changes have been individually reported.
Cytogenetics
No consistent cytogenetic abnormalities have been identified in metanephric adenoma. The gains of chromosomes 7 and 17 noted in papillary renal cell carcinoma, as well as the chromosome gains of 1q, 7q, and 12, and losses of 11p and 16q commonly seen in Wilms' tumor have not been detected in metanephric adenoma.
Genes involved and proteins
Approximately 90% of metanephric adenomas contain a V600E activating mutation in exon 15 of BRAF (Choueiri et al., 2012) . BRAF-mutated metanephric adenomas stain positive for V600E mutation-specific immunohistochemistry (Pinto et al., 2015; Udager et al., 2015) . BRAF mutations are very rare (<1%) or absent in other renal tumor subtypes.
BRAF (v-raf murine sarcoma viral oncogene homolog B1)

Location 7q34
Note BRAF V600E mutations are found in approximately 90% of metanephric adenomas.
